NUVB Nuvation Bio Inc.
Company Analysis
Latest News
🔴 Nuvation Bio falls 4.0% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Nuvation Bio is trading 4.47% up in after-hours trading with no confirmed company-specific catalyst
Nuvation Bio is trading at $7.25, up +4.47% in after-hours trading, with no confirmed company-specific catalyst. • It closed at $6.94 on August 26, 2026. •...
🟢 Nuvation Bio rises 4.4% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
Nuvation Bio Targets $12, Cantor Fitzgerald Cites Promising Cancer Drug Pipeline
Cantor Fitzgerald initiated coverage on Nuvation Bio Inc. with an Overweight rating. The firm established a 12-month price target of $12 per share. This...
Nuvation Bio Gets an FDA Fast Track for Its Brain Cancer Drug — But Can a Niche Market Justify a $2.5 Billion Bet?
Shares of Nuvation Bio jumped 6.0% to $7.24 after the FDA granted Fast Track Designation for the company's oral brain cancer drug targeting a specific mutation...
🟢 Nuvation Bio is trading 6% up in pre-market after FDA Fast Track designation for safusidenib
Nuvation Bio is trading 6.00% up now at $7.24 after the FDA granted Fast Track Designation on August 20, 2026, to investigational safusidenib for IDH1-mutant...
Nuvation Bio Gains FDA Fast Track for Safusidenib Brain Cancer Treatment
Nuvation Bio announced that the FDA granted Fast Track Designation to its investigational drug, safusidenib. The treatment targets IDH1-mutant glioma, a form...
🔴 Nuvation Bio falls 4.4% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Nuvation Bio rises 5.5% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Nuvation Bio is trading 4.1% up today after J.P. Morgan initiated coverage with an Overweight rating
Nuvation Bio is trading 4.1% up at $6.75 after J.P. Morgan initiated coverage on August 18, 2026, with an Overweight rating and a $13 December 2027 price...
🟢 Nuvation Bio is trading 5% up today with no new catalyst identified
Nuvation Bio is trading $6.54 (+5.23%) higher during the August 17, 2026 session, with no new company-specific announcement or scheduled event identified. -...
🔴 Nuvation Bio is trading 4.05% down today with no fresh company-specific catalyst identified
Nuvation Bio is trading 4.05% down at $6.16 despite broader markets moving higher on August 13, 2026; no fresh company-specific announcement clearly explains...
Nuvation Bio's Cancer Drug Is Selling Well — So Why Are Investors Running for the Exit?
Shares of Nuvation Bio dropped 6.2% to $5.98 after the oncology company's second-quarter results delivered an uncomfortable split decision: strong drug sales...
Nuvation Bio's Cancer Drug Is Selling Well — So Why Are Investors Running for the Exit?
Shares of Nuvation Bio dropped 6.2% to $5.98 after the oncology company's second-quarter results delivered an uncomfortable split decision: strong drug sales...
🟢 Nuvation Bio is trading 5% up today after second-quarter revenue beat expectations
Nuvation Bio is trading 4.99% up now at $6.41 after investors reassessed its August 6 earnings. - Second-quarter revenue reached $31.7 million, beating...
🔴 Nuvation Bio is trading 4% down today after a wider-than-expected EPS loss despite strong IBTROZI sales
Nuvation Bio is trading at $6.12 (-4.00%) after its August 6, 2026, earnings showed strong IBTROZI sales but a wider-than-expected loss. - Second-quarter...
🔴 Nuvation Bio is trading 6% down in pre-market after EPS loss misses estimates despite revenue beat
Nuvation Bio is trading 6.17% down now at $5.98 in pre-market after its August 6, 2026 second-quarter earnings release showed an EPS loss of $0.18, worse than...
Nuvation Bio second quarter revenue beats on strong IBTROZI sales, though EPS misses expectations.
Nuvation Bio reported second quarter revenue of $31.7 million, surpassing analyst estimates, driven by strong uptake of its lung cancer drug IBTROZI. However,...
Nuvation Bio Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect Nuvation Bio to report a Q2 2026 loss per share of $0.14 and revenue of $26.53 million, while the current $6.48 stock price suggests...
🟢 Nuvation Bio is trading 4.1% up today on broader market tailwinds
Nuvation Bio is trading at $6.41 (4.1% up), rebounding from recent weakness and moving broadly in line with today’s strong risk-on mood across U.S....